201 related articles for article (PubMed ID: 22533610)
41. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.
Passoni L; Scardino A; Bertazzoli C; Gallo B; Coluccia AM; Lemonnier FA; Kosmatopoulos K; Gambacorti-Passerini C
Blood; 2002 Mar; 99(6):2100-6. PubMed ID: 11877285
[TBL] [Abstract][Full Text] [Related]
42. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
43. Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer.
Gillmore R; Xue SA; Holler A; Kaeda J; Hadjiminas D; Healy V; Dina R; Parry SC; Bellantuono I; Ghani Y; Coombes RC; Waxman J; Stauss HJ
Clin Cancer Res; 2006 Jan; 12(1):34-42. PubMed ID: 16397021
[TBL] [Abstract][Full Text] [Related]
44. CD2/LFA-3 or LFA-1/ICAM-1 but not CD28/B7 interactions can augment cytotoxicity by virus-specific CD8+ cytotoxic T lymphocytes.
de Waal Malefyt R; Verma S; Bejarano MT; Ranes-Goldberg M; Hill M; Spits H
Eur J Immunol; 1993 Feb; 23(2):418-24. PubMed ID: 7679643
[TBL] [Abstract][Full Text] [Related]
45. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
46. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
47. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.
Qian J; Xie J; Hong S; Yang J; Zhang L; Han X; Wang M; Zhan F; Shaughnessy JD; Epstein J; Kwak LW; Yi Q
Blood; 2007 Sep; 110(5):1587-94. PubMed ID: 17515399
[TBL] [Abstract][Full Text] [Related]
48. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
[TBL] [Abstract][Full Text] [Related]
49. General T-cell receptor antagonists to immunomodulate HLA-A2-restricted minor histocompatibility antigen HA-1-specific T-cell responses.
den Haan JM; Mutis T; Blokland E; IJzerman AP; Goulmy E
Blood; 2002 Feb; 99(3):985-92. PubMed ID: 11807003
[TBL] [Abstract][Full Text] [Related]
50. A similarity in peptide cross-reactivity between alloantigen- and nominal antigen-induced CD8+ T cell responses in vitro.
Yu Q; Zhang L; Ouyang L; Gong Y; Liang Z; Shen G; Weng X; Wu X
Immunogenetics; 2013 Mar; 65(3):173-84. PubMed ID: 23233149
[TBL] [Abstract][Full Text] [Related]
51. Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells.
Bae J; Samur M; Munshi A; Hideshima T; Keskin D; Kimmelman A; Lee AH; Dranoff G; Anderson KC; Munshi NC
Oncoimmunology; 2014; 3(12):e970914. PubMed ID: 25941601
[TBL] [Abstract][Full Text] [Related]
52. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
Merindol N; Grenier AJ; Caty M; Charrier E; Duval A; Duval M; Champagne MA; Soudeyns H
J Immunol; 2010 Jul; 185(2):856-66. PubMed ID: 20543110
[TBL] [Abstract][Full Text] [Related]
53. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
[TBL] [Abstract][Full Text] [Related]
54. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
55. Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.
Gritzapis AD; Voutsas IF; Lekka E; Tsavaris N; Missitzis I; Sotiropoulou P; Perez S; Papamichail M; Baxevanis CN
J Immunol; 2008 Jul; 181(1):146-54. PubMed ID: 18566379
[TBL] [Abstract][Full Text] [Related]
56. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
57. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.
Herr W; Schneider J; Lohse AW; Meyer zum Büschenfelde KH; Wölfel T
J Immunol Methods; 1996 May; 191(2):131-42. PubMed ID: 8666832
[TBL] [Abstract][Full Text] [Related]
58. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia.
Bae J; Martinson JA; Klingemann HG
Cell Immunol; 2004 Jan; 227(1):38-50. PubMed ID: 15051513
[TBL] [Abstract][Full Text] [Related]
59. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8
Yu Z; Liu W; He Y; Sun M; Yu J; Jiao X; Han Q; Tang H; Zhang B; Xian Y; Qi J; Gong J; Xin W; Shi G; Shan F; Zhang R; Li J; Wei M
J Hematol Oncol; 2021 Apr; 14(1):71. PubMed ID: 33910591
[TBL] [Abstract][Full Text] [Related]
60. Identification of CD8
Ma N; Liu H; Zhang Y; Liu W; Liang Z; Wang Q; Sun Y; Wang L; Li Y; Ren H; Dong Y
Front Immunol; 2022; 13():927804. PubMed ID: 35967402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
